Literature DB >> 15738745

A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder.

Kristin Mitte1, Peter Noack, Regina Steil, Martin Hautzinger.   

Abstract

A meta-analytic review of the efficacy of pharmacological treatment in generalized anxiety disorder was conducted. The main substance classes were compared: benzodiazepines and azapirones. The impact of methodological variables was investigated such as sample size and use of a placebo run-in. After a comprehensive literature search to May 2002 (via databases, hand search, secondary sources, internet, contact of researchers, and pharmaceutical companies), the results of 48 studies were integrated. Weighted Hedges g was computed and a random-effects analysis was done. Effect sizes were computed for anxiety, depression, and clinical significance. Sensitivity analyses were conducted. Pharmacotherapy was superior to placebo in all symptom categories. Azapirones and benzodiazepines were equally effective. Compliance (as measured by dropout rate) was higher for benzodiazepines. Only sample size was significantly associated with effect size. Pharmacotherapy, especially benzodiazepines and azapirones, is effective in the short-term treatment of patients with generalized anxiety disorder. There was no superiority of 1 drug class in reducing symptomatology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15738745     DOI: 10.1097/01.jcp.0000155821.74832.f9

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  20 in total

Review 1.  Generalised anxiety disorder.

Authors:  Christopher K Gale; Jane Millichamp
Journal:  BMJ Clin Evid       Date:  2011-10-27

2.  Meta-analyses and conflict of interest.

Authors:  Giovanni A Fava
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

Review 3.  Generalised anxiety disorder.

Authors:  Christopher Gale; Oliver Davidson
Journal:  BMJ       Date:  2007-03-17

Review 4.  Generalised anxiety disorder.

Authors:  Christopher K Gale; Jane Millichamp
Journal:  BMJ Clin Evid       Date:  2007-11-20

5.  Pregabalin influences insula and amygdala activation during anticipation of emotional images.

Authors:  Robin L Aupperle; Lakshmi Ravindran; Dharol Tankersley; Taru Flagan; Nathan R Stein; Alan N Simmons; Murray B Stein; Martin P Paulus
Journal:  Neuropsychopharmacology       Date:  2011-03-23       Impact factor: 7.853

Review 6.  Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review.

Authors:  Angelina F Gomez; Abigail L Barthel; Stefan G Hofmann
Journal:  Expert Opin Pharmacother       Date:  2018-05-28       Impact factor: 3.889

7.  Is it Beneficial to Add Pharmacotherapy to Cognitive-Behavioral Therapy when Treating Anxiety Disorders? A Meta-Analytic Review.

Authors:  Stefan G Hofmann; Alice T Sawyer; Kristina J Korte; Jasper A J Smits
Journal:  Int J Cogn Ther       Date:  2009-01-01

Review 8.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

9.  The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum.

Authors:  J Sarris; D J Kavanagh; G Byrne; K M Bone; J Adams; G Deed
Journal:  Psychopharmacology (Berl)       Date:  2009-05-09       Impact factor: 4.530

Review 10.  Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.

Authors:  Keming Gao; David V Sheehan; Joseph R Calabrese
Journal:  Expert Rev Neurother       Date:  2009-08       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.